Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Changzhou Yabang-QH Pharmachem is a China-based veterinary pharmaceutical and API manufacturing company focused primarily on anthelmintic small-molecule products. The company operates as part of the QH group and manufactures veterinary APIs, late-stage intermediates, and related products for domestic and export markets. Its capabilities emphasize cGMP-compliant production, quality and EHS systems, regulatory support such as CEP/ASMF/VMF filings, and contract manufacturing for multinational pharmaceutical customers. The business appears to be commercially oriented rather than a drug-development biotech, with strength in antiparasitic chemistry, process development, and large-scale manufacturing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Changzhou Yabang-QH Pharmachem.